about
PRL-3 phosphatase is implicated in ovarian cancer growthStrategies to diagnose ovarian cancer: new evidence from phase 3 of the multicentre international IOTA study.Evaluating the risk of ovarian cancer before surgery using the ADNEX model to differentiate between benign, borderline, early and advanced stage invasive, and secondary metastatic tumours: prospective multicentre diagnostic study.Simple ultrasound rules to distinguish between benign and malignant adnexal masses before surgery: prospective validation by IOTA groupExpression of DNA repair genes in ovarian cancer samples: biological and clinical considerations.External validation of diagnostic models to estimate the risk of malignancy in adnexal masses.Unique features of the mode of action of ET-743.Profiling cancer gene mutations in longitudinal epithelial ovarian cancer biopsies by targeted next-generation sequencing: a retrospective study.IGFBP-4 tumor and serum levels are increased across all stages of epithelial ovarian cancer.Application of RNA-Seq transcriptome analysis: CD151 is an Invasion/Migration target in all stages of epithelial ovarian cancer.Regulator of G-protein signaling 5 (RGS5) protein: a novel marker of cancer vasculature elicited and sustained by the tumor's proangiogenic microenvironment.The zinc finger gene ZIC2 has features of an oncogene and its overexpression correlates strongly with the clinical course of epithelial ovarian cancer.Systematic lymphadenectomy in ovarian cancer at second-look surgery: a randomised clinical trialEmbryo transfer following in vitro maturation and cryopreservation of oocytes recovered from antral follicles during conservative surgery for ovarian cancerAdjuvant sequential chemo and radiotherapy improves the oncological outcome in high risk endometrial cancerA phase II randomised clinical trial comparing cisplatin, paclitaxel and ifosfamide with cisplatin, paclitaxel and epirubicin in newly diagnosed advanced epithelial ovarian cancer: long-term survival analysisPhase I study of SU5416, a small molecule inhibitor of the vascular endothelial growth factor receptor (VEGFR) in refractory pediatric central nervous system tumors.microRNA-181a has a critical role in ovarian cancer progression through the regulation of the epithelial-mesenchymal transition.Lymphadenectomy in uterine low-grade endometrial stromal sarcoma: an analysis of 19 cases and a literature review.Delivery delay with neoadjuvant chemotherapy for cervical cancer patients during pregnancy: a series of nine cases and literature review.Risk of malignancy in unilocular cysts: a study of 1148 adnexal masses classified as unilocular cysts at transvaginal ultrasound and review of the literature.Gynecologic cancers in pregnancy: guidelines of a second international consensus meeting.Primary brain tumours, meningiomas and brain metastases in pregnancy: report on 27 cases and review of literature.Long-term follow-up of patients with an isolated ovarian recurrence after conservative treatment of epithelial ovarian cancer: review of the results of an international multicenter study comprising 545 patients.Ovarian cancer in pregnancy.ALDH enzymatic activity and CD133 positivity and response to chemotherapy in ovarian cancer patients.Predicting the risk of malignancy in adnexal masses based on the Simple Rules from the International Ovarian Tumor Analysis group.Long-term results of fertility-sparing treatment compared with standard radical surgery for early-stage epithelial ovarian cancerThe contribution of a collagen-fibrin patch (Tachosil) to prevent the postoperative lymphatic complications after groin lymphadenectomy: a double institution observational study.Trypsinogen 4 boosts tumor endothelial cells migration through proteolysis of tissue factor pathway inhibitor-2.KRas-LCS6 polymorphism does not impact on outcomes in ovarian cancer.Platinum, anthracycline, and alkylating agent-based chemotherapy for ovarian carcinosarcoma.The role of pelvic and aortic lymphadenectomy at second look surgery in apparent early stage ovarian cancer after inadequate surgical staging followed by adjuvant chemotherapy.A phase II clinical trial of topotecan and carboplatin in patients with newly diagnosed advanced epithelial ovarian cancer.High-performance liquid chromatography/tandem mass spectrometry for the quantitative analysis of a novel taxane derivative (BAY59-8862) in biological samples and characterisation of its metabolic profile in rat bile samples.Large polyp of the small intestine: an unexpected metastasis of ovarian carcinosarcoma.DNA-damage response gene polymorphisms and therapeutic outcomes in ovarian cancer.Tailoring systematic lymphadenectomy in high-risk clinical early stage endometrial cancer: the role of 18F-FDG PET/CT.MiRNA landscape in stage I epithelial ovarian cancer defines the histotype specificities.Imaging in gynecological disease (8): ultrasound characteristics of recurrent borderline ovarian tumors.
P50
Q28275403-2E8A9D01-FBB6-4F75-B513-F5B93E5F31E6Q30404969-52F7F452-D15D-42B6-B775-ED4BBFF7B264Q30428244-A4EEE72F-8626-4A89-828F-71E8D6D505B7Q30478027-FBDABFC1-C7E0-49EB-B1FB-6B5A1ED7E7FFQ33788841-CE9E0C31-6E8E-4388-89D8-46D222CE1EB4Q34235622-B12C152D-998B-4820-BF5A-F61F91CDE818Q34686690-AE6587B5-27B3-48CB-BFD5-5EAD46935A98Q35595719-C1AE9D0B-DF6F-432B-A1D0-D574599E25D5Q35735751-EAC4FACB-9C26-46CD-A254-9857D414ED4AQ35785330-4652D340-9408-49CF-B186-1ABF6B1C3A4AQ35823514-06F7396A-1190-4622-A369-4F511A59B3ADQ36091016-B8515CA8-5698-4CE9-9E36-BCE768A248BFQ36184223-94188BEB-3393-49D4-92AB-731A9944AAA2Q36198823-0454155E-A6E6-45CD-A5A4-2BCE5F423CCFQ36205599-691DB525-80F2-4C52-9192-A63B5A580F5AQ36484521-002693FA-2E03-42E1-BA6A-155D8446981CQ37416895-BB32075F-1B25-4139-9EA0-5E3F24535609Q37497239-6406D7B8-C28D-4650-8796-7469C862B3E1Q37807249-65782E18-6AC5-4644-98DA-DD88E40F8806Q38007299-E12C5FE3-CAA8-4AC7-9505-DCEE352D6118Q38045841-21861783-AF22-48A7-B6F4-E9D6BEA38E33Q38180375-7CCC4644-A54C-4177-B5F5-E11470B8DBE9Q38196613-D47597EA-3F1F-4CEE-878B-562A8E197C20Q38543344-19986508-F6A6-47A0-B619-CE28615AAB66Q39060866-0B8E8629-FC40-4D5C-93FC-F7B18817B3CFQ39779683-A6778C94-4D48-46FA-98A8-8ECF9674E0E7Q40072293-F6F9033F-AF80-4882-8787-BE6DF860F10EQ40617006-DC94BB55-6C74-4971-8B72-1400282A76F9Q40834006-31BB4277-A8B5-4FAC-B14A-C9077D29886BQ41535597-C87C59D5-39F7-4442-941C-128FDBE1E7C8Q41949668-3E36040D-B0A9-4A00-92FE-E22C507290F8Q43263671-1AA5E1C9-31E8-4859-A2BD-5CCAA36FE1ECQ43547059-0F644E88-0136-46B9-A7AD-2E9C6CDB6C19Q43726817-DF0A7555-3D1A-4B05-9DCD-0DE52B3E0E13Q43743500-B7E3A74E-48BD-4065-9727-AE66215EBE32Q44146902-22B22DA6-B225-4FCD-AF55-64CD700E1566Q44386340-E81B5EEE-73FA-4CC2-9839-237D77FAA308Q45327793-9E3A3724-AB9B-43A6-AF34-D591D0D738F0Q45915221-5B1FE002-7B1F-4C96-9F6F-286D51B75D04Q46066166-CEDBD673-D1A1-4BD2-9168-BBA85E9AFE89
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Robert Fruscio
@ast
Robert Fruscio
@en
Robert Fruscio
@es
Robert Fruscio
@nl
Robert Fruscio
@sl
type
label
Robert Fruscio
@ast
Robert Fruscio
@en
Robert Fruscio
@es
Robert Fruscio
@nl
Robert Fruscio
@sl
prefLabel
Robert Fruscio
@ast
Robert Fruscio
@en
Robert Fruscio
@es
Robert Fruscio
@nl
Robert Fruscio
@sl
P1053
F-8542-2011
P106
P1153
16042230300
P21
P31
P3829
P496
0000-0001-5688-2194